Hims & Hers Health (NYSE:HIMS) Given New $36.00 Price Target at Bank of America

Posted by Brian Himes on Jul 1st, 2026

Hims & Hers Health (NYSE:HIMS – Get Free Report) had its price target boosted by stock analysts at Bank of America from $25.00 to $36.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. Bank of America‘s price target would suggest a potential upside of 4.23% from the stock’s previous close.

Several other research firms have also recently issued reports on HIMS. UBS Group set a $23.00 target price on shares of Hims & Hers Health in a research report on Friday, May 22nd. Citigroup increased their price target on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 12th. TD Cowen cut their price target on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a research note on Friday, March 27th. Truist Financial lifted their price target on shares of Hims & Hers Health from $18.00 to $23.00 and gave the company a “hold” rating in a report on Friday, May 22nd. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and a consensus price target of $30.10.

Read Our Latest Stock Analysis on HIMS

Hims & Hers Health Stock Performance

NYSE HIMS opened at $34.54 on Wednesday. The business’s 50-day moving average price is $28.18 and its 200 day moving average price is $26.31. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $70.43. The company has a market capitalization of $7.99 billion, a PE ratio of -383.76, a price-to-earnings-growth ratio of 47.73 and a beta of 2.37. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The business had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. During the same quarter last year, the firm earned $0.20 EPS. The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. On average, research analysts predict that Hims & Hers Health will post 0.05 earnings per share for the current year.

Insiders Place Their Bets

In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the transaction, the chief operating officer directly owned 432,124 shares of the company’s stock, valued at $13,611,906. This trade represents a 3.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Patrick Harrison Carroll sold 23,726 shares of the business’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $35.00, for a total transaction of $830,410.00. Following the completion of the sale, the insider directly owned 181,861 shares of the company’s stock, valued at $6,365,135. The trade was a 11.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 163,973 shares of company stock valued at $4,859,194. 11.76% of the stock is owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several large investors have recently modified their holdings of the stock. Western Wealth Management LLC bought a new stake in Hims & Hers Health in the first quarter valued at about $166,000. NewEdge Advisors LLC grew its position in shares of Hims & Hers Health by 25.7% in the 1st quarter. NewEdge Advisors LLC now owns 38,173 shares of the company’s stock worth $792,000 after acquiring an additional 7,800 shares in the last quarter. Avidity Partners Management LP acquired a new position in shares of Hims & Hers Health in the 1st quarter worth approximately $1,557,000. Bank of America Corp DE increased its holdings in shares of Hims & Hers Health by 194.4% in the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after acquiring an additional 2,877,550 shares during the last quarter. Finally, Sunbelt Securities Inc. increased its holdings in shares of Hims & Hers Health by 5,444.7% in the 1st quarter. Sunbelt Securities Inc. now owns 23,565 shares of the company’s stock valued at $489,000 after acquiring an additional 23,140 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.